- Home
- NAGE vs LENZ Comparison
NAGE vs LENZ Comparison
Compare NAGE & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | LENZ |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.7M | 278.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAGE | LENZ |
|---|---|---|
| Price | $3.63 | $7.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $16.00 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 893.0K | 823.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | $16.51 | $50.42 |
| Revenue Next Year | $14.58 | $197.16 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $6.83 |
| 52 Week High | $14.66 | $50.19 |
Technical Indicators
Market Signals| Indicator | NAGE | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 32.65 |
| Support Level | N/A | N/A |
| Resistance Level | $5.22 | $10.34 |
| Average True Range (ATR) | 0.22 | 0.65 |
| MACD | -0.12 | -0.17 |
| Stochastic Oscillator | 2.96 | 14.00 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.